Fajun Nan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fajun Nan has a total of 376 co-authors. Here are the top co-authors by number of shared publications:
- Jingya Li
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
10 shared publications Min Gu
State Key Laboratory of Drug Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
10 shared publications- Linhai Chen
State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
9 shared publications Xin Xie
Shanghai Institute of Materia Medica
9 shared publications- Xin Xie
State Key Laboratory of Drug Research, The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
9 shared publications Yangming Zhang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China; Burgeon Therapeutics Co., Ltd, Shanghai 201203, P.R. China
8 shared publications
Latest Publications
- 19 October 2026
- Published by American Chemical Society (ACS) in ACS Catalysis
Direct Amidination of Alkenes Via C–H Activation of Pyridinyl Formimidamide Synthon
Alkenes are among the most abundant and versatile feedstocks in synthetic chemistry, yet methods for their direct and regioselective conversion into nitrogen-containing frameworks remain scarce. In particular, the direct catalytic amidination of alkenes has remained underdeveloped. Herein, we report a rhodium-catalyzed anti-Markovnikov amidination of alkenes using a stable pyridinyl formimidamide synthon. This reaction enables the direct installation of amidine moieties onto a wide range of alkenes, including styrenes, aliphatic alkenes, and challenging internal alkenes that undergo efficient chain-walking with high regioselectivity and broad functional group tolerance, accommodating unprotected amines, phenols, and halides. The resulting pyridyl amidines can be readily transformed into amides, carboxylic acids and esters, establishing a practical platform for alkene diversification. Notably, late-stage functionalization of complex bioactive molecules, including cyclosporine A, FK506, and quinine etc., provides access to previously inaccessible analogues. Mechanistic investigations, highlighted by the crystallographic capture of a key rhodium–aminopyridinyl formimidamide intermediate, provide compelling evidence for the proposed catalytic cycle. Collectively, this work not only fills a critical gap in alkene functionalization but also offers a concise and general route to high-value nitrogen-containing architectures.
- 19 October 2026
- Published by American Chemical Society (ACS) in ACS Catalysis
Direct Amidination of Alkenes Via C–H Activation of Pyridinyl Formimidamide Synthon
Alkenes are among the most abundant and versatile feedstocks in synthetic chemistry, yet methods for their direct and regioselective conversion into nitrogen-containing frameworks remain scarce. In particular, the direct catalytic amidination of alkenes has remained underdeveloped. Herein, we report a rhodium-catalyzed anti-Markovnikov amidination of alkenes using a stable pyridinyl formimidamide synthon. This reaction enables the direct installation of amidine moieties onto a wide range of alkenes, including styrenes, aliphatic alkenes, and challenging internal alkenes that undergo efficient chain-walking with high regioselectivity and broad functional group tolerance, accommodating unprotected amines, phenols, and halides. The resulting pyridyl amidines can be readily transformed into amides, carboxylic acids and esters, establishing a practical platform for alkene diversification. Notably, late-stage functionalization of complex bioactive molecules, including cyclosporine A, FK506, and quinine etc., provides access to previously inaccessible analogues. Mechanistic investigations, highlighted by the crystallographic capture of a key rhodium–aminopyridinyl formimidamide intermediate, provide compelling evidence for the proposed catalytic cycle. Collectively, this work not only fills a critical gap in alkene functionalization but also offers a concise and general route to high-value nitrogen-containing architectures.
- 22 June 2026
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 36 (8) , 679-693
A patent review of GPR84 receptor antagonists (2020-present)
1. G protein-coupled receptor 84 (GPR84), first identified in 2001 [1,2], is a rhodopsin-like Class A GPCR that serves as a key metabolic sensor. It can be activated by medium-chain fatty acids (MC...
- 22 June 2026
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 36 (8) , 679-693
A patent review of GPR84 receptor antagonists (2020-present)
1. G protein-coupled receptor 84 (GPR84), first identified in 2001 [1,2], is a rhodopsin-like Class A GPCR that serves as a key metabolic sensor. It can be activated by medium-chain fatty acids (MC...
- Open Access
- 28 January 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (5) , 2756-2772
Small molecules modulate the biomolecular condensates and liquid‒liquid phase separation
- 28 January 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (5) , 2756-2772
Open AccessSmall molecules modulate the biomolecular condensates and liquid‒liquid phase separation
- Open Access
- 12 December 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (51) , 14181-14186
Biomimetic Total Synthesis of Dispirocochlearoids A–C and Related Ganoderma Meroterpenoid Dimers
The first total synthesis of the anti-inflammatory Ganoderma meroterpenoid dimers dispirocochlearoids A-C, along with five of their diastereomers─potential unreported natural products─has been accomplished using a convergent strategy that leveraged common intermediates derived from dayaolingzhiol M. The synthesis features several key steps: a hetero-Diels-Alder reaction, a hydrolysis/double-bond migration cascade to assemble the D/E-bicyclic core, and a condensation/intramolecular aldol/lactonization cascade that constructs the final B/C-bicyclic system of dispirocochlearoids A-C.
- 12 December 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (51) , 14181-14186
Open AccessBiomimetic Total Synthesis of Dispirocochlearoids A–C and Related Ganoderma Meroterpenoid Dimers
The first total synthesis of the anti-inflammatory Ganoderma meroterpenoid dimers dispirocochlearoids A-C, along with five of their diastereomers─potential unreported natural products─has been accomplished using a convergent strategy that leveraged common intermediates derived from dayaolingzhiol M. The synthesis features several key steps: a hetero-Diels-Alder reaction, a hydrolysis/double-bond migration cascade to assemble the D/E-bicyclic core, and a condensation/intramolecular aldol/lactonization cascade that constructs the final B/C-bicyclic system of dispirocochlearoids A-C.
- 22 October 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (11) , 2149-2166.e9
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
- 22 October 2025
- Published by Elsevier in Cell Metabolism
- Vol. 37 (11) , 2149-2166.e9
The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα
- 12 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118258
Novel thieno[2,3-b]pyridine derivatives protect islet through DRAK2 kinase inhibition
- 12 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118258
Novel thieno[2,3-b]pyridine derivatives protect islet through DRAK2 kinase inhibition
- 16 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 15598-15616
Discovery of Novel Tridentate Alkenyl Diacid Derivatives as Potent ATP Citrate Lyase Inhibitors for the Treatment of Hepatocellular Carcinoma
Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), with enhanced de novo lipogenesis playing a critical role in tumor progression. ATP citrate lyase (ACLY), linking carbohydrate metabolism to lipid biosynthesis, has emerged as a promising therapeutic target in HCC. Herein, we report the development of a series of novel tridentate alkenyl diacid derivatives as potent ACLY inhibitors. Guided by molecular docking and structure-activity relationship studies, we identified compound F28, which exhibited potent ACLY inhibitory activity (IC50 = 0.87 ± 0.09 μM) and favorable pharmacokinetic properties. Compound F28 demonstrated antiproliferative activity in vitro across various cancer cell lines and attenuated lipogenesis in JHH7 and HepG2 cells. The administration of compound F28 reduced tumor burden and liver fibrosis in a high-fat diet combined with a chemotoxic agent-induced HCC mouse model. These results position compound F28 as a promising lead compound for the further development of ACLY inhibitors in HCC therapy.
- 16 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 15598-15616
Discovery of Novel Tridentate Alkenyl Diacid Derivatives as Potent ATP Citrate Lyase Inhibitors for the Treatment of Hepatocellular Carcinoma
Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), with enhanced de novo lipogenesis playing a critical role in tumor progression. ATP citrate lyase (ACLY), linking carbohydrate metabolism to lipid biosynthesis, has emerged as a promising therapeutic target in HCC. Herein, we report the development of a series of novel tridentate alkenyl diacid derivatives as potent ACLY inhibitors. Guided by molecular docking and structure-activity relationship studies, we identified compound F28, which exhibited potent ACLY inhibitory activity (IC50 = 0.87 ± 0.09 μM) and favorable pharmacokinetic properties. Compound F28 demonstrated antiproliferative activity in vitro across various cancer cell lines and attenuated lipogenesis in JHH7 and HepG2 cells. The administration of compound F28 reduced tumor burden and liver fibrosis in a high-fat diet combined with a chemotoxic agent-induced HCC mouse model. These results position compound F28 as a promising lead compound for the further development of ACLY inhibitors in HCC therapy.
- Open Access
- 9 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
General Amidination of Alkenes via Rh-Mediated C–H Activation of Pyridinyl Formimidamide
The synthesis of high-value nitrogen-containing compounds (e.g., amidines or amides) from olefins under catalytic conditions is extremely valuable in synthetic chemistry, but general methods for such synthesis remain scarce. We develop an Rh-catalyzed solution using 2-aminopyridinyl formimidamide as a versatile new synthon for alkene amidination. This operationally simple protocol achieves excellent regioselectivity across styrenes, aliphatic alkenes, and nonterminal alkenes that undergo efficient chain-walking to participate in the reaction. This method tolerates substrates with unprotected amines, alcohols, and halides groups. The late-stage functionalization of complex molecules (FK506, quinine, and cyclosporin A etc.) and the diversification of amidines to amides, acids, and esters make the method broad utility. Our strategy overcomes the fundamental limitations of alkene difunctionalization, thereby establishing a general route to high-value nitrogen architectures
- 9 July 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessGeneral Amidination of Alkenes via Rh-Mediated C–H Activation of Pyridinyl Formimidamide
The synthesis of high-value nitrogen-containing compounds (e.g., amidines or amides) from olefins under catalytic conditions is extremely valuable in synthetic chemistry, but general methods for such synthesis remain scarce. We develop an Rh-catalyzed solution using 2-aminopyridinyl formimidamide as a versatile new synthon for alkene amidination. This operationally simple protocol achieves excellent regioselectivity across styrenes, aliphatic alkenes, and nonterminal alkenes that undergo efficient chain-walking to participate in the reaction. This method tolerates substrates with unprotected amines, alcohols, and halides groups. The late-stage functionalization of complex molecules (FK506, quinine, and cyclosporin A etc.) and the diversification of amidines to amides, acids, and esters make the method broad utility. Our strategy overcomes the fundamental limitations of alkene difunctionalization, thereby establishing a general route to high-value nitrogen architectures
- Open Access
- 2 April 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (14)
Phosphatidylinositol 4,5-bisphosphate activation mechanism of human KCNQ5
The human voltage-gated potassium channels KCNQ2, KCNQ3, and KCNQ5 can form homo- and heterotetrameric channels that are responsible for generating the neuronal M current and maintaining the membrane potential stable. Activation of KCNQ channels requires both the depolarization of membrane potential and phosphatidylinositol 4,5-bisphosphate (PIP 2 ). Here, we report cryoelectron microscopy structures of the human KCNQ5–calmodulin (CaM) complex in the apo, PIP 2 -bound, and both PIP 2 - and the activator HN37-bound states in either a closed or an open conformation. In the closed conformation, a PIP 2 molecule binds in the middle of the groove between two adjacent voltage-sensing domains (VSDs), whereas in the open conformation, one additional PIP 2 binds to the interface of VSD and the pore domain, accompanying structural rearrangement of the cytosolic domain of KCNQ and CaM. The structures, along with electrophysiology analyses, reveal the two different binding modes of PIP 2 and elucidate the PIP 2 activation mechanism of KCNQ5.
- 2 April 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (14)
Open AccessPhosphatidylinositol 4,5-bisphosphate activation mechanism of human KCNQ5
The human voltage-gated potassium channels KCNQ2, KCNQ3, and KCNQ5 can form homo- and heterotetrameric channels that are responsible for generating the neuronal M current and maintaining the membrane potential stable. Activation of KCNQ channels requires both the depolarization of membrane potential and phosphatidylinositol 4,5-bisphosphate (PIP 2 ). Here, we report cryoelectron microscopy structures of the human KCNQ5–calmodulin (CaM) complex in the apo, PIP 2 -bound, and both PIP 2 - and the activator HN37-bound states in either a closed or an open conformation. In the closed conformation, a PIP 2 molecule binds in the middle of the groove between two adjacent voltage-sensing domains (VSDs), whereas in the open conformation, one additional PIP 2 binds to the interface of VSD and the pore domain, accompanying structural rearrangement of the cytosolic domain of KCNQ and CaM. The structures, along with electrophysiology analyses, reveal the two different binding modes of PIP 2 and elucidate the PIP 2 activation mechanism of KCNQ5.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1783-1794
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects
Objective: This Phase I study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BGT-002, a novel ATP-citrate lyase (ACLY) inhibitor, in healthy Chinese adults. Methods: This study included three parts: Part I (single-ascending-dose study), Part II (multiple-ascending-dose study), and Part III (food effect study). A total of 104 healthy subjects were enrolled in the study and were given BGT-002 tablet or placebo per protocol requirements. Blood samples were collected for pharmacokinetic and pharmacodynamic analysis. Safety was assessed by clinical examinations and adverse events. Results: In Part I, BGT-002 demonstrated rapid absorption with a Tmax of 0.67 to 1.75 hours, and slow elimination with a T1/2 of 24.53 to 72.86 hours, prolonged with increased dosages. Cmax and AUC0-∞ ranged from 1.55 to 48.39 μg/mL, and 31.09 to 2930.69 h·μg/mL, respectively. In Part II, the accumulation index (Rac) of Cmax and AUCtau following 14 days of consecutive administration were 3.53 to 3.62 and 5.29 to 5.59, respectively, with a dose-proportionality PK profile. The levels of total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), and low-density lipoprotein cholesterol (LDL-C) were maximally decreased by 15.80%, 18.50%, and 22.37%, respectively. In Part III, the geometric mean ratio (90% CI) of fed to fasting condition in Cmax and AUC0-∞ of BGT-002 were 73.11% and 98.36%, respectively, indicating a minor food effect on the absorption rate. Across the study, two cases of Grade 3 adverse events (elevated blood triglycerides) were reported, both of which were assessed as not related to BGT-002. No serious adverse events were observed. Conclusion: BGT-002 demonstrated favorable safety, tolerability, and lipid-lowering effects, supporting its potential for further clinical development. Clinical Trial Registration: ChiCTR2200057793(https://www.chictr.org.cn/showproj.html?proj=160210); ChiCTR2300067474(https://www.chictr.org.cn/showproj.html?proj=182183); ChiCTR2300067472(https://www.chictr.org.cn/showproj.html?proj=184079).
- 1 March 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 1783-1794
Open AccessA Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects
Objective: This Phase I study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BGT-002, a novel ATP-citrate lyase (ACLY) inhibitor, in healthy Chinese adults. Methods: This study included three parts: Part I (single-ascending-dose study), Part II (multiple-ascending-dose study), and Part III (food effect study). A total of 104 healthy subjects were enrolled in the study and were given BGT-002 tablet or placebo per protocol requirements. Blood samples were collected for pharmacokinetic and pharmacodynamic analysis. Safety was assessed by clinical examinations and adverse events. Results: In Part I, BGT-002 demonstrated rapid absorption with a Tmax of 0.67 to 1.75 hours, and slow elimination with a T1/2 of 24.53 to 72.86 hours, prolonged with increased dosages. Cmax and AUC0-∞ ranged from 1.55 to 48.39 μg/mL, and 31.09 to 2930.69 h·μg/mL, respectively. In Part II, the accumulation index (Rac) of Cmax and AUCtau following 14 days of consecutive administration were 3.53 to 3.62 and 5.29 to 5.59, respectively, with a dose-proportionality PK profile. The levels of total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), and low-density lipoprotein cholesterol (LDL-C) were maximally decreased by 15.80%, 18.50%, and 22.37%, respectively. In Part III, the geometric mean ratio (90% CI) of fed to fasting condition in Cmax and AUC0-∞ of BGT-002 were 73.11% and 98.36%, respectively, indicating a minor food effect on the absorption rate. Across the study, two cases of Grade 3 adverse events (elevated blood triglycerides) were reported, both of which were assessed as not related to BGT-002. No serious adverse events were observed. Conclusion: BGT-002 demonstrated favorable safety, tolerability, and lipid-lowering effects, supporting its potential for further clinical development. Clinical Trial Registration: ChiCTR2200057793(https://www.chictr.org.cn/showproj.html?proj=160210); ChiCTR2300067474(https://www.chictr.org.cn/showproj.html?proj=182183); ChiCTR2300067472(https://www.chictr.org.cn/showproj.html?proj=184079).